Timeline of the COVID-19 pandemic

Stem Cell Therapy For Long Haul Covid In LA Announced By Springs Rejuvenation

Retrieved on: 
Tuesday, January 24, 2023
COVID-19, Ageing, Cardiovascular disease, Infection, National Center for Health Statistics, Government budget balance, Brain, Timeline of the COVID-19 pandemic, Rejuvenation, Needle, B cell, Pulmonary fibrosis, Respiratory system, Laboratory, Fatigue, Sleep, FDA, Myalgia, Headache, National Center for Regenerative Medicine, Immune system, Patient, Medical statistics, Severe acute respiratory syndrome coronavirus 2, Inflammation, Stem cell, Vaccine, Pharmaceutical industry

The renowned Los Angeles-based stem cell therapy clinic Springs Rejuvenation announces a new therapy for patients suffering from long Covid.

Key Points: 
  • The announcement outlines the clinic's innovative approach to tackling the causes and symptoms of what is known as 'Long Haul Covid'.
  • Stem cell therapy also bolsters the immune system to prevent reinfection and reduce the intensity of symptoms.
  • Covid patients suffering from lung damage can also find relief through the clinic's stem cell solutions.
  • Springs Rejuvenation's stem cell treatments are non-invasive and offer an effective alternative to prescription medication for the relief of chronic disorders.

Leading Stem Cell Clinic in the US Develops First Real "Stem Cell Face Mask"

Retrieved on: 
Tuesday, December 6, 2022
B cell, Peptide, Stem-cell therapy, Timeline of the COVID-19 pandemic, MSC, Neck pain, Arthralgia, Nerve injury, Psoriasis, Stem cell, Skin, Dementia, Health, Patient, COVID, Vampire, MS, Hyaluronic acid, Alzheimer's disease, Back pain, Medicine, Spring, Spinal cord injury, Quality of life, COVID 19, Acne, Osteoarthritis, Degenerative disease, Exosome, Crohn's disease, IV, COVID-19, Rejuvenation, ACL, Stroke, Multiple sclerosis, Dentistry, Pharmaceutical industry

"We created face mask born from the most successful therapies used to heal skin and grow collagen.

Key Points: 
  • "We created face mask born from the most successful therapies used to heal skin and grow collagen.
  • Springs Rejuvenation gained most of its notoriety though stem cell and exosome joint injections of professional athletes.
  • Springs Rejuvenation has been collecting data from IV stem cell and exosome therapy for many of the nations top medical conditions.
  • Located thought the US Springs Rejuvenation is the nations leading stem cell center with locations in Miami Florida, Atlanta Georgia, Austin Texas, and Los Angeles.

University of California Health launches Long COVID education series to expand access to care

Retrieved on: 
Friday, December 2, 2022
Accreditation Council for Continuing Medical Education, Knowledge, Rheumatology, COVID-19, Emergency medicine, MPH, FACOG, Pediatrics, University, Health, News, University of California, San Diego, Research, University of California, Davis, AMA, Accreditation Council, Faculty, Continuing medical education, Patient, PASC, UCLA, UCSF, Neurology, Hospital, Physician, Education, David Geffen School of Medicine at UCLA, Accreditation, UC, UCI, CME, Timeline of the COVID-19 pandemic, Cardiology, Medicine, Pharmaceutical industry

OAKLAND, Calif., Dec. 2, 2022 /PRNewswire-PRWeb/ -- University of California Health has created a video education series to inform and educate health care providers about best practices and the latest research on screening, managing symptoms and making specialty referrals for patients with post-COVID symptoms.

Key Points: 
  • OAKLAND, Calif., Dec. 2, 2022 /PRNewswire-PRWeb/ -- University of California Health has created a video education series to inform and educate health care providers about best practices and the latest research on screening, managing symptoms and making specialty referrals for patients with post-COVID symptoms.
  • The COVID-19 pandemic has been a mass disabling event that has led to long-term consequences for patients, health care providers, and the nation's system of health care, especially in medically underserved communities.
  • "By educating, equipping, and empowering more providers in the battle against the very real impact of Long COVID, we are helping expand access to care for this condition."
  • University of California Health comprises six academic health centers, 20 health professional schools, a Global Health Institute and systemwide services that improve the health of patients and the University's students, faculty, and employees.

EQS-News: Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?

Retrieved on: 
Friday, November 11, 2022
MRNA, Immunity, Protein, Health, NYSE, Vaccine, Someren-Eind, NSU, BNTX, Exosome, Food, Factor X, Advertising, Research, Risk, Center, Hyaluronic acid, MicroRNA, Diagnosis, BLA, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Timeline of the COVID-19 pandemic, EVS, PFE, NASDAQ, PPX, Regenerative medicine, Kumasi Centre for Collaborative Research, Johnson & Johnson, Virus, Company, Biologics license application, Science, JNJ, OTCQB, Clinical trial, Patient, BioNTech, Therapy, Pfizer, Infection, Seminal vesicles, Degenerative disease, FDA, Pharmaceutical industry

Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?

Key Points: 
  • Is It Time To Pay Attention To This Acellular Biologic Pioneer That Says Its Clinical Trials Are Cheaper And Easier?
  • The company hit a significant milestone in October 2020 when the FDA granted expanded access for patients to be treated with their flagship therapeutic, Zofin.
  • According to Organicell, Zofin is naturally derived and, therefore, only requires 30 patients to complete Phase I/II trials of clinical trials.
  • Phase III trials should require only 250-300 patients, while clinical trials are currently enrolling and anticipated to be completed within 24 months.

electroCore Provides Select Third Quarter 2022 Financial Guidance

Retrieved on: 
Friday, October 14, 2022
International, Vagus nerve, Time, Hypertension, Migraine, Growth, Bradycardia, Patient, Tachycardia, Cluster headache, Timeline of the COVID-19 pandemic, VA, United States Department of Defense, Private Securities Litigation Reform Act, Adolescence, Company, Transcutaneous electrical nerve stimulation, Industry, Department, ECOR, Neurology, United States Department of Veterans Affairs, Department of Defence, Nerve conduction study, Hemicrania continua, Pain, Nature, Indometacin, Adult, United, NVN, Medication overuse headache, Skin, Overalls, GLOBE, European, A luta continua, ElectroCore, Headache, Hearing, Hypotension, Safety, FDA, COVID-19, Terminology, Prescription, Medical device, Video game, Pharmaceutical industry

ROCKAWAY, N.J., Oct. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the Company) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary financial guidance for the third quarter of 2022.

Key Points: 
  • ROCKAWAY, N.J., Oct. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the Company) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary financial guidance for the third quarter of 2022.
  • Preliminary unaudited financial guidance for the third quarter of 2022:
    Revenue: The Company anticipates reporting third quarter 2022 revenue of approximately $1,976,000.
  • 113 VA and DoD military treatment facilities purchased gammaCore products through September 30, 2022, as compared to 96 through the third quarter of 2021.
  • Cash Position: The Company ended the third quarter of 2022 with approximately $21.9 million of cash and cash equivalents, compared to $26.6 millionas of the end of the second quarter of 2022.

Sermo Surveys Reveals 87% of Global Physicians Feel There is a Lack of Clinical Guidelines on How to Treat Long Covid in Patients

Retrieved on: 
Tuesday, October 11, 2022
Research, Mental Health, Infectious Diseases, Clinical Trials, Public Policy, Government, Healthcare Reform, General Health, Health, Science, Other Science, Physician, Myocarditis, Timeline of the COVID-19 pandemic, Degenerative disease, Barometer, Intelligence, Patient, Mental health, Pandemic fatigue, MD, Frustration, IBD, Frazier Healthcare Partners, HCP, Hearing, Collaboration, View, Pharmaceutical industry, Vaccine, COVID-19, Sermo

The survey of more than 1,100 global physicians found that 86% felt there is a lack of clinical guidance on how to diagnose Long Covid and 87% reported that they felt there is a lack of clinical guidance on how to treat Long Covid in patients.

Key Points: 
  • The survey of more than 1,100 global physicians found that 86% felt there is a lack of clinical guidance on how to diagnose Long Covid and 87% reported that they felt there is a lack of clinical guidance on how to treat Long Covid in patients.
  • Long Covid is Top-of-mind for Physicians and Patients Alike:
    Long Covid is a pressing issue for many physicians.
  • 62% of surveyed physicians reported that they are seeing an increase in Long Covid symptoms in patients in their practice and 71% reported seeing an increase in patients being concerned about Long Covid.
  • U.S. Physicians Are Recommending the New Bivalent Covid Booster, But Patients Arent Interested:
    Booster apathy is high among already vaccinated patients.

Global Urological Endoscope (MedCore) Market Report 2022-2028: Market Size, Market Shares, Market Forecasts, Market Growth Rates, Units Sold, and Average Selling Prices - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 27, 2022
Biotechnology, Medical Supplies, Surgery, Health, Medical Devices, Hospitals, Health Technology, Other Health, Adoption, Olympus, Cystoscopy, Boston Scientific, Growth, Timeline of the COVID-19 pandemic, Endoscopy, BPH, CAGR, Medical device

The "Urological Endoscope Market Report with COVID Impact - Global - 2022- 2028 - MedCore" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Urological Endoscope Market Report with COVID Impact - Global - 2022- 2028 - MedCore" report has been added to ResearchAndMarkets.com's offering.
  • Overall, the global urological endoscope market was valued at nearly $982 million in 2021.
  • The full report suite on the global market for urological endoscopes includes single-use, rigid and flexible reusable cystoscopes, single-use, semi-rigid and flexible reusable ureteroscopes, rigid resectoscopes and rigid nephroscopes.
  • For context in this report, rigid and semi-rigid endoscope is implicitly referencing as a reusable endoscope.

Global Urinary Incontinence (MedCore) Market Report 2022-2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 20, 2022
Health, General Health, Data source name, Neuro, Competitive analysis, Ageing, Timeline of the COVID-19 pandemic, FDA, Disruptive innovation, TVT, Population, Russian Industrial Leaders Index, 13th Air Support Operations Squadron, COVID19, Urinary incontinence, Central, Female, Male, FDA recall policies, Central and Eastern Europe, Windows Internal Database, SIS, TOT, SWOT, Boston Scientific, Mergers and acquisitions, Incontinence, CAGR, Medical imaging, Baltic states

The "Urinary Incontinence Market Report with COVID Impact - Global - 2022 - 2028 - MedCore" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Urinary Incontinence Market Report with COVID Impact - Global - 2022 - 2028 - MedCore" report has been added to ResearchAndMarkets.com's offering.
  • The complete report suite on the global market for urinary incontinence device market includes urethral bulking agents (UBAs) and incontinence slings.
  • The urinary incontinence sling market is segmented into female and male urinary incontinence slings.
  • Global Urinary Incontinence Sling Market - Further segmented into:
    Female and male urinary incontinence slings.

Todos Medical Establishes Botanical Supplement Manufacturing Capabilities to Support Tollovid Global Expansion and Initiates CBD-A Production

Retrieved on: 
Wednesday, August 31, 2022
Cancer prevention, Cell cycle, Good manufacturing practice, CEO, Technology, Infection, TBIA, Monocyte, Research, Neuron, Neurodegeneration, Legislation, Brain, Distillation, Solution, Synthase, U.S. Securities and Exchange Commission, Pressure, SOP, Water supply, TMB-2, Method, CGMP, Alzheimer's disease, GLOBE, PCR, Medicine, Plasma, Lymphocyte, Company, Immune system, Biotechnology, COGS, Cancer, Knowledge, Marketing, Amazon, Apoptosis, OTCQB, Capsule, Pharmaceutical industry, Medical imaging, CBD, Pharma, Timeline of the COVID-19 pandemic

The facility is capable of producing Tollovid, the Companys majority owned subsidiary 3CL Pharmas Ltd.s 3CL protease inhibitor immune support dietary supplement, as well as other immune support supplement ingredients that could ultimately be added to new Tollovid formulations, including vitamin C and CBD-A.

Key Points: 
  • The facility is capable of producing Tollovid, the Companys majority owned subsidiary 3CL Pharmas Ltd.s 3CL protease inhibitor immune support dietary supplement, as well as other immune support supplement ingredients that could ultimately be added to new Tollovid formulations, including vitamin C and CBD-A.
  • The facility is currently equipped with over $2,000,000 in botanical manufacturing equipment for the production of supplements and drugs.
  • It can manufacture products from various botanical extract embodiments, including capsules, tinctures, gummies, drinks and syrups.
  • With this manufacturing initiative, we can bring our cost of goods sold (COGS) to a level where we can compete in the supplement market internationally.

StemCyte Announces FDA Approval of IND for a Phase II Clinical Trial to Treat Post-COVID Syndrome Using Umbilical Cord Blood Stem Cell Therapy

Retrieved on: 
Monday, August 29, 2022
Inflammation, COVID-19, Fatigue, The Lancet, Timeline of the COVID-19 pandemic, Pain, Weakness, PCS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Government, View, Brain, Disability, Dizziness, Stroke, Degenerative disease, Hope, Food, Anxiety, Autoimmunity, Multimedia, Journal, Depression, Severe acute respiratory syndrome coronavirus 2, Infection, Prevalence, FDA, Therapy, Cancer, Cerebral palsy, Health, COVID, Sleep, Patient, Palpitations, Pharmaceutical industry

BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte is pleased to announce it has received approval from the U.S. Food and Drug Administration (FDA) for their Phase II clinical trial for Post-COVID Syndrome (or PCS) using umbilical cord blood stem cell therapy.

Key Points: 
  • BALDWIN PARK, Calif., Aug. 29, 2022 /PRNewswire/ -- Southern California cord blood regenerative therapeutics company StemCyte is pleased to announce it has received approval from the U.S. Food and Drug Administration (FDA) for their Phase II clinical trial for Post-COVID Syndrome (or PCS) using umbilical cord blood stem cell therapy.
  • StemCyte aims to treat PCS by infusing umbilical cord blood that is capable of anti-inflammation and tissue repair.
  • StemCyte's Phase II clinical trial aims to effectively treat PCS by infusing umbilical cord blood that is capable of anti-inflammation and tissue repair for long-term effect.
  • StemCyte considers umbilical cord blood banking its core competence, while actively pursuing new regenerative cell therapy indications, including spinal cord injury, Long COVID treatment, acute stroke, cerebral palsy and cancers.